Kallikrein 4 antibody (AA 242-254)

Catalog No. ABIN636259

Product Details anti-Kallikrein 4 Antibody

Target: Kallikrein 4 (KLK4) (Kallikrein-Related Peptidase 4 (KLK4))

Binding Specificity: AA 242-254

Reactivity: Human

Host: Rabbit

Clonality: Polyclonal

Conjugate: This Kallikrein 4 antibody is un-conjugated

Application: Western Blotting (WB)

Purification: Affinity chromatography purified

Immunogen: KLK-L1 antibody was raised in rabbit using AA 242-254 [KFTEWIEKTVQAS] of the human 39 kDa KLK-L1 (KLK4) protein as the immunogen.

Isotype: IgG

Application Details

Application Notes: WB: 1:500-1:1,000
Optimal conditions should be determined by the investigator.

Restrictions: For Research Use only

Handling

Concentration: Lot specific

Buffer: Affinity purified IgG supplied in PBS with 0.02 % NaN3.

Preservative: Sodium azide

Precaution of Use: This product contains Sodium Azide: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.

Handling Advice: Avoid repeated freeze/thaw cycles.
Dilute only prior to immediate use.

Storage: 4 °C/-20 °C

Storage Comment: Store at 4 °C for short term storage. Aliquot and store at -20 °C for long term storage.

Target Details for Kallikrein 4

Target: Kallikrein 4 (KLK4) (Kallikrein-Related Peptidase 4 (KLK4))

Alternative Name: KLK-L1 (KLK4 Products)

Synonyms: ESMP1 antibody, KLK-L1 antibody, PSTS antibody, Prss17 antibody, AI2A1 antibody, ARM1 antibody, EMSP antibody, EMSP1 antibody, PRSS17 antibody, kallikrein antibody, Emsp1 antibody, kallikrein related-peptidase 4 (prostase, enamel matrix, prostate) antibody, kallikrein related peptidase 4 antibody, kallikrein-related peptidase 4 antibody, Klk4 antibody, KLK4 antibody

Background: Kallikreins are a subgroup of serine proteases and are implicated in carcinogenesis. A novel Kallikrein gene Prostase/KLK-L1 (also known as KLK4) is expressed and is up-regulated by androgens and progestins. KLK-L1 may be involved in the pathogenesis and/or progression of prostate, breast, and possibly other malignancies.

Pathways: Complement System